MGTX MeiraGTx Holdings plc

NASDAQ
$13.52

MeiraGTx Holdings plc (MGTX) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.47 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.7% since its last earnings release on August 13, 2026.

MeiraGTx Holdings plc Beat Consensus Estimates
Thursday, August 13, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($0.47)
Rev est $1.55M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $13.10

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MeiraGTx Holdings plc

MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow